Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
[EN] QUINOLINONE DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLINONE EN TANT QU'INHIBITEURS DE PARP
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2009053373A1
公开(公告)日:2009-04-30
Compounds of formula (I) wherein R1, R2, R3, R4, R5, Z and n have defined meanings, the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary ammonium salts and the stereochemically isomeric forms thereof, and their use for the treatment of PARP- mediated disorders.
QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS
申请人:Vialard Jorge Eduardo
公开号:US20100168065A1
公开(公告)日:2010-07-01
The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I)
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, n, m and X have defined meanings.
QUINOLINONE DERIVATIVES AS PARP INHIBITORS
申请人:Angibaud Patrick René
公开号:US20100222348A1
公开(公告)日:2010-09-02
Compounds of formula (I):
wherein R
1
, R
2
, R
3
, R
4
, R
5
, Z and n have defined meanings, the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary ammonium salts and the stereochemically isomeric forms thereof, and their use for the treatment of PARP-mediated disorders.